Uncategorized

It was only a matter of time

First a big congratulations to Andy Reid and the Kansas City Chiefs, kudos as well to the 49ers who had one heck of a season. With football now over we can turn our attention to the cornfields of Iowa, New Hampshire and beyond as the race for the Democratic Presidential nomination heats up and people actually start voting, imagine that democracy in action. Another race which is heating up is...

There is no cure

Since it’s the Friday before the SuperBowl and nothing much is really going on we decided to check in on an old friend. Since CGM has replaced BGM as the standard for glucose monitoring, since LifeScan is no longer owned by JNJ and Bayer is no longer Bayer there aren’t many BGM companies left that actually report results. So this morning we checked in on our friends at Roche who...

The Right Mix

While reading through Lilly’s earnings release, we were struck by several items. Having followed Lilly for over 20 years we remember a time long ago when their diabetes franchise appeared to be on the verge of extinction. Back then the company seemed to have lost their way while their rival Novo Nordisk was powering ahead. Today there is little doubt that Lilly has not just regained their mojo but is...

Now we’ll see

This morning CVS announced a plan to eliminate the out of pocket cost for branded diabetes medications. Per a company issued press release; “CVS Health (NYSE: CVS) today announced a new solution eliminating member out-of-pocket costs associated with all diabetes prescription medications, including insulin.” CVS noted that patients on average spend $467.24 per year out of pocket with 12% of their patient population spending over $1,000 per year. CVS is just the...

Early Reports – Plus a New Feature

This morning Tandem announced they would conduct their fourth quarter and full year conference call on Monday February 24th. As we have noted we don’t expect the launch of the Control IQ to materially impact results. However now that the Control IQ has passed through the FDA and is now in the hands of patients, we have some thoughts on the impact the system will make going forward. First and foremost...

Data plus AI = ?

Before we begin today, I’d like to take a moment to mourn the tragic passing of Kobe Bryant, his daughter and the other people on the helicopter. Kobe was more than one of the greatest basketball players of all time and his presence will be sorely missed. Our prayers go out to his family and sports fans across the globe. We have lost an all-time great. Over the weekend besides being...

The time will come

As most everyone knows we are not stock market prognosticators, yes there have been times when we will come out and say it’s a good time to buy or sell but these are rare occasions. However we do receive lots of questions on the companies we follow and many center on whether it’s time to buy or sell. One company that has caught everyone’s attention is Livongo. Given that digital...

Yes it does matter

To be honest we’re not sure who said “Those who cannot remember the past are condemned to repeat it” but we know it wasn’t anyone at Abbott. Yesterday the company continued to backtrack from their initial comments that Libre2 would not just receive FDA approval but would garner this approval with an iCGM designation. Since Libre2 was submitted to the FDA the company who initially expressed supreme confidence has been...

Where oh where is Libre2

As expected, Abbott posted strong fourth quarter and full year results for Libre. Let’s take a quick look at the numbers in the fourth quarter global sales reached $691 million, full year global just over $2.5 Billion. No matter how you slice these numbers they are impressive, but the scary part is they are just the tip of the iceberg. As we keep noting CGM adoption will only increase in...

It’s that time again

As we transition from conference mode to earnings season some key questions remain unanswered. Tomorrow morning earnings season kicks off when Abbott reports full year and fourth quarter results. We have no doubt that Libre sales continue to progress well, that really isn’t an issue. The issue that’s on everyone’s mind is just when Libre2 will make it through the FDA. Just to recap a little from JPM the company didn’t...